Jan Johannessen Sells 2,200 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Jan Johannessen sold 2,200 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $47.91, for a total value of $105,402.00. Following the completion of the sale, the director directly owned 17,754 shares in the company, valued at approximately $850,594.14. The trade was a 11.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $49.06 on Wednesday. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $51.00. The business has a fifty day moving average of $37.62 and a 200-day moving average of $32.17. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -38.33 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. The company’s revenue was up 16.9% on a year-over-year basis. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the company. Campbell & CO Investment Adviser LLC grew its stake in Twist Bioscience by 227.6% during the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock worth $1,328,000 after buying an additional 32,792 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Twist Bioscience by 14.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after acquiring an additional 184,726 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Twist Bioscience by 62.8% during the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock valued at $35,533,000 after acquiring an additional 487,052 shares in the last quarter. New York State Common Retirement Fund boosted its position in Twist Bioscience by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after purchasing an additional 71,777 shares during the period. Finally, American Century Companies Inc. increased its holdings in Twist Bioscience by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock valued at $31,801,000 after purchasing an additional 100,978 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on TWST. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Barclays boosted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Finally, Evercore increased their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $45.88.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.